XLO

7.4301.07%
CF

Christopher Frankenfield

CFO & COO

Mr. Christopher Frankenfield, also known as Chris, is Chief Operating Officer at Xilio Therapeutics, Inc. since August 2023 and also serves as its CFO since August 2024. He served as Chief Legal and Administrative Officer at Xilio Therapeutics, Inc. since August 08, 2022 until August 2023 and served as General Counsel. Mr. Frankenfield is an accomplished biotechnology professional with experience supporting and counselling companies on complex legal issues, transactions and corporate matters. Prior to Xilio, Mr. Frankenfield served as Vice President of corporate legal affairs at Blueprint Medicines Corporation. At Blueprint Medicines, he served on the company’s management team and led public company reporting activities, advised on capital markets strategies, supported multiple successful equity offerings and executed collaborations and Partnerships with Roche, CStone Pharmaceuticals and Clementia Pharmaceuticals, a wholly-owned subsidiary of Ipsen. Prior to Blueprint Medicines, Mr. Frankenfield was a senior associate at Wilmer Cutler Pickering Hale and Dorr LLP, with a focus on strategic transactions, securities regulations and compliance and corporate governance. Mr. Frankenfield began his career at PricewaterhouseCoopers LLP where he advised clients on complex commercial disputes and investigations. He received his B.A. in Economics from The College of William & Mary and his J.D. from the University of Virginia School of Law.

Positions